Vincerx Pharma, Inc. - VINC STOCK NEWS

PALO ALTO, Calif., Feb. 09, 2022 – Vincerx Pharma, a biopharmaceutical company focused on innovative cancer therapeutics, announced participation in the upcoming SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The management team will engage in a fireside chat on February 17, 2022, at 1:40 PM ET. Investors can access the live webcast and archived recordings via Vincerx's website. The company aims to address unmet medical needs with its advanced oncology therapies, including a pipeline developed from an exclusive partnership with Bayer.

Vincerx Pharma (Nasdaq: VINC) announced positive preclinical data for VIP236, a novel small molecule-drug conjugate targeting aggressive tumors. Published in the journal Cancers, the research highlights VIP236's ability to deliver a potent chemotherapy payload directly to cancer cells while sparing healthy tissue. The study showcases a 40-fold increase in drug delivery to tumors compared to normal tissues and demonstrates superior tumor targeting and tolerability in various cancer models. Vincerx plans to advance VIP236 into clinical trials in late 2022.

Vincerx Pharma, Inc. (Nasdaq: VINC) announced the initiation of its Phase 1 dose-escalation study for VIP152 in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) and Richter Syndrome (RS). The first patient has been dosed, marking the second clinical trial launched this year. Previous data indicated VIP152's improved selectivity and potency compared to other CDK9 inhibitors, showing cytotoxic activity in CLL samples. The study will assess VIP152's efficacy in patients who have failed prior treatments, with plans to expand to Phase 2 studies in late 2022.

Vincerx Pharma's VIP152, a selective CDK9 inhibitor, shows superior selectivity and potency compared to other CDK9 inhibitors at the ASH Annual Meeting. Data presented on December 11, 2021, highlighted VIP152's effectiveness in treating high-grade B-cell lymphoma and chronic lymphocytic leukemia. The inhibitor demonstrated robust downregulation of MYC and MCL-1 proteins, with promising preclinical results expected to translate into clinical advancements. Vincerx is currently enrolling studies for relapsed/refractory aggressive lymphoma and CLL patients.

Vincerx Pharma (Nasdaq: VINC) has received Orphan Drug Designation from the European Commission for VIP152, a PTEFb/CDK9 inhibitor intended for treating diffuse large B-cell lymphoma (DLBCL). This milestone highlights VIP152's potential for addressing unmet medical needs in rare cancers. Vincerx is advancing Phase 1b studies of VIP152, which includes two expansion arms focusing on various aggressive lymphomas and advanced solid tumors. The designation provides benefits like market exclusivity and protocol assistance within the EU.

Vincerx Pharma, a clinical-stage biopharmaceutical company, announced a webinar on December 11, 2021, to discuss data on VIP152, its lead asset for chronic lymphocytic leukemia and diffuse large B-Cell lymphoma, presented at the ASH Annual Meeting. Key opinion leaders John C. Byrd and Rosa Lapalombella will present, focusing on the treatment landscape and VIP152's mechanism of action. VIP152 is a selective CDK9 inhibitor showing early clinical activity, especially in double-hit DLBCL patients, with indications of effective oncogene suppression.

Vincerx Pharma announced progress in its Phase 1b study of VIP152 for MYC-driven aggressive lymphomas and advanced solid tumors. The study continues despite challenges from COVID-19, and the company is set to initiate a new dose escalation study for CLL in late 2021. Financially, Vincerx strengthened its balance sheet with a $50 million private placement, increasing cash to $122.8 million. However, the company reported a net loss of $24.5 million for Q3 2021, reflecting significant R&D and operational expenses.

Vincerx Pharma (Nasdaq: VINC) has announced the acceptance of two abstracts related to its selective CDK9 inhibitor VIP152 for presentation at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. One abstract highlights VIP152's ability to induce complete regression of high-grade B-cell lymphoma, while the second focuses on its efficacy in chronic lymphocytic leukemia. Both presentations will occur on December 11, 2021, at specific times and locations during the conference, underscoring the company's ongoing commitment to addressing cancer treatment needs.

Vincerx Pharma (Nasdaq: VINC) announced a definitive agreement on September 15, 2021, to sell 3.5 million shares of common stock at $14.50 each, aimed at bolstering its financial position. This private placement, led by investors including Deerfield Management and Point72 Asset Management, is expected to close on September 20, 2021. The company plans to utilize the net proceeds for working capital and to further its clinical evaluations, including ongoing studies of VIP152, a CDK9 inhibitor. As of June 30, 2021, Vincerx had $85.6 million in cash and cash equivalents.